-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★Dry goodsCAR-T therapy shows great power, and the cellular immune industry welcomes market opportunities ★The most potential drug transporter-exosomesYimai New Observation Click on the picture and register now July 7, 2021 Japan/MedClub News/--XNK Therapeutics recently announced that the Phase II clinical study of its autologous natural killer (NK) cell therapy candidate CellProtect has been included in the first patient.
This drug is compatible with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab) is used in combination to treat patients with multiple myeloma
.
Multiple myeloma (MM) is a malignant tumor with abnormal proliferation of plasma cells in the bone marrow, ranking third in the global hematological malignancies
.
Traditional chemotherapy is the standard method for the treatment of multiple myeloma, but due to the special pathogenesis of hematological tumors, MM often requires high-dose chemotherapy, which has obvious side effects and is prone to drug resistance
.
Since there are no obvious symptoms in the early stage of the disease, and the recurrence rate of multiple myeloma after treatment is quite high, MM is often the object of doctors' headaches, so people began to explore new treatment options
.
NK cell therapy kills tumor cells.
Many multiple myeloma cells down-regulate the expression of MHC I molecules to evade the monitoring of cytotoxic CD8+ T cells.
However, NK cells can recognize and respond to these cells lacking their own phenotype, and ultimately Causes the lysis of target cells
.
In addition to directly inducing cytotoxicity, NK cells also respond to transformed cells by producing pro-inflammatory cytokines (including IFNγ and TNF)
.
In addition to the ability of these pleiotropic proteins to enhance the response of cytotoxic CD8+ T cells, they also have powerful anti-proliferation, anti-angiogenesis and pro-apoptosis effects on cancer cells
.
ADCC (antibody-dependent cell-mediated cytotoxicity) is another key mechanism of NK cell-mediated killing of cancer cells.
This activity can be exploited by using therapeutic monoclonal antibodies that target tumor-associated antigens: a.
The combination of the Fc portion of the antibody and the FcγR of NK cells activates NK cells and induces the release of effector molecules, including perforin and granzyme
.
b.
A bispecific antibody targeting CD16 or CD38 on the NK cell side at one end and a tumor-specific antigen at the other end can enhance the specific binding between NK cells and tumor cells
.
▲ADCC therapy based on NK cells (picture source: bing) "Combining NK cells that mediate antibody-dependent cytotoxicity (ADCC) with targeting antibodies is an attractive concept
.
Our idea is to design a It can reduce the synergistic effect of toxicity and help patients with multiple myeloma stay disease-free
.
This is the first study initiated by researchers to randomly assign patients to different NK cell therapy treatment groups.
" Karolinska Medicine Said Hareth Nahi, associate professor of the Academy and lead researcher of the study
.
▲Hareth Nahi, associate professor of Karolinska Institutet (picture source: reference 2) NK cell combination program improves antibody efficiency.
NK cells can not only directly kill tumor cells, but also have a powerful immunomodulatory effect
.
NK indirectly regulates the immune system, promotes the maturation of DC cells, and increases the number of cytotoxic T cells that infiltrate the tumor
.
Not only the more active NK cells infused can kill tumor cells, but the B cells and T cells that are increased by NK cells can also be used to kill tumor cells
.
At the same time, the increase of T cells solves the phenomenon that the CD38 antibody has no role in the body of immunocompromised patients, resulting in ineffective treatment
.
Recommended reading: A new strategy for NK cell treatment of solid tumors, the antibody-NK cell coupling clinical trial has been launchedYiMeng broke the news XNK Therapeutics is a clinical-stage immunotherapy company dedicated to the development of new NK cell therapies to prevent and treat cancer
.
The company has established a leading position in the clinical development and manufacturing of autologous NK cell products using its proprietary technology platform
.
The company's platform technology and leading research drug candidate CellProtect have the ideal characteristics of targeting cancer, avoiding the environmental rejection of allogeneic cell products
.
It is foreseeable that this product will become a key component of future cancer treatment strategies
.
In November 2020, CellProtect has been granted orphan drug designation by the U.
S.
Food and Drug Administration (FDA) as a major research drug candidate for the treatment of multiple myeloma (MM)
.
XNK has also obtained orphan drug qualification in the European Union.
Obtaining the orphan drug qualification for the treatment of multiple myeloma from the FDA is a key step in the development of XNK's main research drug candidates
.
"The inclusion of the first patient in the Phase II clinical study this time is a key step in the development of XNK
.
" said Johan Liwing, CEO of XNK Therapeutics.
"Although our main drug candidate is now entering Phase II, we are also committed to bringing our The clinical development plan is advanced to other indications based on the first phase I/II human study"
.
▲Johan Liwing, CEO of XNK Therapeutics (picture source: XNK official website) References: 1.
https:// ii-study-in-multiple-myeloma-301324022.
html2.
https://ki.
se/en/medh/hareth-nahi-group Yimai Ke has always been committed to the cutting-edge technology, industry trends, industry insights and other original creations of bio-innovative drugs According to news reports, all-media high-end matrix users reached 160,000+, of which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
This drug is compatible with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab) is used in combination to treat patients with multiple myeloma
.
Multiple myeloma (MM) is a malignant tumor with abnormal proliferation of plasma cells in the bone marrow, ranking third in the global hematological malignancies
.
Traditional chemotherapy is the standard method for the treatment of multiple myeloma, but due to the special pathogenesis of hematological tumors, MM often requires high-dose chemotherapy, which has obvious side effects and is prone to drug resistance
.
Since there are no obvious symptoms in the early stage of the disease, and the recurrence rate of multiple myeloma after treatment is quite high, MM is often the object of doctors' headaches, so people began to explore new treatment options
.
NK cell therapy kills tumor cells.
Many multiple myeloma cells down-regulate the expression of MHC I molecules to evade the monitoring of cytotoxic CD8+ T cells.
However, NK cells can recognize and respond to these cells lacking their own phenotype, and ultimately Causes the lysis of target cells
.
In addition to directly inducing cytotoxicity, NK cells also respond to transformed cells by producing pro-inflammatory cytokines (including IFNγ and TNF)
.
In addition to the ability of these pleiotropic proteins to enhance the response of cytotoxic CD8+ T cells, they also have powerful anti-proliferation, anti-angiogenesis and pro-apoptosis effects on cancer cells
.
ADCC (antibody-dependent cell-mediated cytotoxicity) is another key mechanism of NK cell-mediated killing of cancer cells.
This activity can be exploited by using therapeutic monoclonal antibodies that target tumor-associated antigens: a.
The combination of the Fc portion of the antibody and the FcγR of NK cells activates NK cells and induces the release of effector molecules, including perforin and granzyme
.
b.
A bispecific antibody targeting CD16 or CD38 on the NK cell side at one end and a tumor-specific antigen at the other end can enhance the specific binding between NK cells and tumor cells
.
▲ADCC therapy based on NK cells (picture source: bing) "Combining NK cells that mediate antibody-dependent cytotoxicity (ADCC) with targeting antibodies is an attractive concept
.
Our idea is to design a It can reduce the synergistic effect of toxicity and help patients with multiple myeloma stay disease-free
.
This is the first study initiated by researchers to randomly assign patients to different NK cell therapy treatment groups.
" Karolinska Medicine Said Hareth Nahi, associate professor of the Academy and lead researcher of the study
.
▲Hareth Nahi, associate professor of Karolinska Institutet (picture source: reference 2) NK cell combination program improves antibody efficiency.
NK cells can not only directly kill tumor cells, but also have a powerful immunomodulatory effect
.
NK indirectly regulates the immune system, promotes the maturation of DC cells, and increases the number of cytotoxic T cells that infiltrate the tumor
.
Not only the more active NK cells infused can kill tumor cells, but the B cells and T cells that are increased by NK cells can also be used to kill tumor cells
.
At the same time, the increase of T cells solves the phenomenon that the CD38 antibody has no role in the body of immunocompromised patients, resulting in ineffective treatment
.
Recommended reading: A new strategy for NK cell treatment of solid tumors, the antibody-NK cell coupling clinical trial has been launchedYiMeng broke the news XNK Therapeutics is a clinical-stage immunotherapy company dedicated to the development of new NK cell therapies to prevent and treat cancer
.
The company has established a leading position in the clinical development and manufacturing of autologous NK cell products using its proprietary technology platform
.
The company's platform technology and leading research drug candidate CellProtect have the ideal characteristics of targeting cancer, avoiding the environmental rejection of allogeneic cell products
.
It is foreseeable that this product will become a key component of future cancer treatment strategies
.
In November 2020, CellProtect has been granted orphan drug designation by the U.
S.
Food and Drug Administration (FDA) as a major research drug candidate for the treatment of multiple myeloma (MM)
.
XNK has also obtained orphan drug qualification in the European Union.
Obtaining the orphan drug qualification for the treatment of multiple myeloma from the FDA is a key step in the development of XNK's main research drug candidates
.
"The inclusion of the first patient in the Phase II clinical study this time is a key step in the development of XNK
.
" said Johan Liwing, CEO of XNK Therapeutics.
"Although our main drug candidate is now entering Phase II, we are also committed to bringing our The clinical development plan is advanced to other indications based on the first phase I/II human study"
.
▲Johan Liwing, CEO of XNK Therapeutics (picture source: XNK official website) References: 1.
https:// ii-study-in-multiple-myeloma-301324022.
html2.
https://ki.
se/en/medh/hareth-nahi-group Yimai Ke has always been committed to the cutting-edge technology, industry trends, industry insights and other original creations of bio-innovative drugs According to news reports, all-media high-end matrix users reached 160,000+, of which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institutions accounted for more than 5%
.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.
